Correction: Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer

Oncotarget. 2024 Feb 22;15:142. doi: 10.18632/oncotarget.28523.NO ABSTRACTPMID:38386812 | PMC:PMC10883681 | DOI:10.18632/oncotarget.28523

Source: Oncotarget - February 22, 2024 Category: Cancer & Oncology Authors: Maryam Zanjirband Nicola Curtin Richard J Edmondson John Lunec Source Type: research